News from the BioRN Cluster

Home  >>  News from the BioRN Cluster

Heidelberg University: DFG Funding For Heidelberg Collaborative Research Centres

On May 24, 2018, Posted by , In News, By , With Comments Off on Heidelberg University: DFG Funding For Heidelberg Collaborative Research Centres

Ruperto Carola succeeds with three consortia in the latest approval round. Heidelberg University succeeded in gaining support from the German Research Foundation (DFG) in the latest approval round, receiving funding for three research networks. Two Collaborative Research Centres (CRC) in Heidelberg Medicine, the “Reactive Metabolites as a Cause of Diabetic…

BioRN Lounge welcomed Prof. Steffen Rupp from Fraunhofer IGB

On May 17, 2018, Posted by , In Press Releases, By , With Comments Off on BioRN Lounge welcomed Prof. Steffen Rupp from Fraunhofer IGB

Heidelberg, 17.05.2018 BioRN Lounge: Prof. Steffen Rupp from Fraunhofer IGB talked about: ”Innate Immunity in 3D-Infection models: From simple Screening Systems to complex Immune Cell supplemented Skin Models” Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to…

EVI: European-African partnership to advance the development of a Leishmania vaccine

On May 16, 2018, Posted by , In News, With Comments Off on EVI: European-African partnership to advance the development of a Leishmania vaccine

Phase II clinical trials in Sudan of a therapeutic vaccine to prevent post kala azar dermal leishmaniasis to be supported by European & Developing Countries Clinical Trials Partnership Heidelberg, 16 May 2018 Fresh funding from the European & Developing Countries Clinical Trials Partnership (EDCTP) has been secured by a consortium…

DKFZ: “Universal antibodies” disarm various pathogens

On May 15, 2018, Posted by , In News, With Comments Off on DKFZ: “Universal antibodies” disarm various pathogens

Scientists from the German Cancer Research Center (DKFZ) have been studying how the immune system succeeds in keeping pathogens in check. For the first time, the researchers have now discovered antibodies that are capable of disarming not only one specific bacterium but a whole variety of microorganisms at once. The…

EMBL: Celgene joins Open Targets

On May 15, 2018, Posted by , In News, With Comments Off on EMBL: Celgene joins Open Targets

May 2nd 2018 Celgene has joined Open Targets, the public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation Open Targets was founded in 2014 by EMBL-EBI, GSK and the Wellcome Sanger Institute The Open Targets Platform allows researchers to investigate causal links between…

DKFZ/HD Uni Hospital/EMBL: Genetic analysis for certain childhood brain tumors soon a standard-of-care?

On May 14, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ/HD Uni Hospital/EMBL: Genetic analysis for certain childhood brain tumors soon a standard-of-care?

An international team of researchers from the Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), the European Molecular Biology Laboratory (EMBL) and the German Cancer Consortium (DKTK) together with colleagues at the St. Jude Children’s Research Hospital in Memphis and the Hospital for Sick Children in Toronto has summarized…

DKFZ: High science distinction for Michael Baumann

On May 9, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: High science distinction for Michael Baumann

At its 100th Annual Meeting, the American Radium Society honored Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ), with the Janeway Gold Medal. The medal, which is awarded for outstanding contributions in cancer therapy, is one of the most prestigious distinctions in radiation oncology. Michael…

BioMed X and Merck extend research collaboration in oncology

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on BioMed X and Merck extend research collaboration in oncology

BioMed X announced the start of a new research project in collaboration with Merck at its Innovation Center in Heidelberg. The new team will focus on the identification of novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.     Dr. Jan Mauer, who joined the BioMed X…

EMBL – CRISPR: from clipping scissors to word processor

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on EMBL – CRISPR: from clipping scissors to word processor

Barcodes are used in a new way in the MAGESTIC platform, adding a new level of precision to CRISPR gene editing. Credit: Kelly Irvine/NIST Using the gene-editing tool CRISPR to snip at DNA is often akin to using scissors to edit a newspaper article. You can cut out words, but it’s…

Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

On May 4, 2018, Posted by , In News, By , , With Comments Off on Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the official launch of its Redirected Optimized Cell Killing (ROCK™) platform. Based on the company’s long-standing expertise in drug development and protein engineering, the ROCK™ platform enables the generation of both NK…

EMBL: Protein stability and solubility during cell cycle

On May 3, 2018, Posted by , In News, By , , With Comments Off on EMBL: Protein stability and solubility during cell cycle

  Dividing cell colored in a heat gradient, highlighting the variation in proteins’ thermal stability within and between different cell cycle stages. IMAGE: Aleksandra Krolik / EMBL EMBL scientists uncover large solubility and thermal stability changes of proteins during cell cycle The cell cycle is a highly dynamic process that…

University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

On May 2, 2018, Posted by , In News, By , , With Comments Off on University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

A novel vaccine candidate against the causative agent of malaria tropica, the most severe form of human malaria, has now been successfully tested for safety, tolerability and immunogenicity (ability to produce antibodies). Experts of the Department of Clinical Pharmacology and Pharmacoepidemiology of the University Hospital Heidelberg (directed by Prof. Dr….

European QuickFire Challenge for startups – Apply to receive €100,000 + @JLABS residency

On April 25, 2018, Posted by , In News, By , With Comments Off on European QuickFire Challenge for startups – Apply to receive €100,000 + @JLABS residency

European Innovation QuickFire Challenge! Innovators with ideas, technologies, and solutions that improve human healthcare and impact the European ecosystem can now apply for up to €100,000 in grants and one year of residency at an available JLABS location, including access to the global JLABS community. Encouraged applications from companies working…

A booked out BioRN Lounge welcomed Prof. Andreas Trumpp from Hi-STEM

On April 25, 2018, Posted by , In Press Releases, By ,, , With Comments Off on A booked out BioRN Lounge welcomed Prof. Andreas Trumpp from Hi-STEM

Heidelberg, 25.04.2018 BioRN Lounge Prof. Andreas Trumpp from HI-STEM talked about “Stem Cells and Cancer: From Molecular Mechanism to Clinical Trials” Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and…

DKFZ/Heidelberg University: ERC Advanced Grants for Hellmut Augustin and Christof Niehrs

On April 23, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ/Heidelberg University: ERC Advanced Grants for Hellmut Augustin and Christof Niehrs

The European Research Council ERC’s Advanced Grants promote visionary projects of fundamental research. This year, Hellmut Augustin (University of Heidelberg and DKFZ) and Christof Niehrs (University of Mainz and DKFZ) received the prestigious funding. Hellmut Augustin © DKFZ The European Research Council, set up in 2007, promotes fundamental research in…

Cleavage Product of Alzheimer’s Key Protein APP Stimulates Nerve Cell Communication

On April 17, 2018, Posted by , In Research Article, By ,, , With Comments Off on Cleavage Product of Alzheimer’s Key Protein APP Stimulates Nerve Cell Communication

Neuroprotective role of APPsα: A histological section through the hippocampus is depicted in the background. The red staining shows APPsα in neuronal cell bodies. The green staining shows the dendritic processes of nerve cells. Source: Max Richter, Müller research group A cleavage product of the Alzheimer’s APP protein stimulates nerve…

Press Release – Round Table discussion with the Ministry of Economic Affairs of Baden-Württemberg

On April 11, 2018, Posted by , In Press Releases, With Comments Off on Press Release – Round Table discussion with the Ministry of Economic Affairs of Baden-Württemberg

Heidelberg, 11.04.2018 The BioRN Cluster hosted on April 10th a round table discussion with Ms. Köchel and Ms. Krüger from the Ministry of Economic Affairs, Labour and Housing of Baden-Württemberg (Cluster and Regional Politic Unit). From the left: Prof. Stefan Meuer, Dr. Jörg Rauch, Dr. Friedrich Richter, Dr. Julia Schaft,…

EMBL: PDX Finder – Free global portal for cancer models

On April 9, 2018, Posted by , In News, By , With Comments Off on EMBL: PDX Finder – Free global portal for cancer models

First global online catalogue of PDX models facilitates collaboration and helps cancer researchers save valuable time The European Bioinformatics Institute (EMBL-EBI) and The Jackson Laboratory (JAX) have jointly developed the first open cancer research portal for Patient Derived Xenograft (PDX) models. The freely available PDX Finder is hosted by EMBL-EBI…

DKFZ: Blood test indicates risk of developing Alzheimer’s disease

On April 9, 2018, Posted by , In Research Article, By ,, , With Comments Off on DKFZ: Blood test indicates risk of developing Alzheimer’s disease

A newly developed blood test may indicate Alzheimer’s disease on average eight years before the clinical diagnosis. This was demonstrated by scientists from the Ruhr University Bochum (RUB), the German Cancer Research Center (DKFZ) and the Saarland Cancer Registry with a large population-based cohort study from the Saarland. Pathological deposits…

New member: Welcome to PEKKIP Oncology Alliance in our cluster

On April 4, 2018, Posted by , In News, By , With Comments Off on New member: Welcome to PEKKIP Oncology Alliance in our cluster

We are happy to welcome in our cluster PEKKIP Oncology Alliance.   “Fighting cancer needs genius and expertise – but prior to all it needs cooperation.” Ahmet Sami Pekkip – CEO PEKKIP Oncology Alliance have an excellent network of internationally renowned key opinion leaders at hand. They use this pool…